SOUTH SAN FRANCISCO - Cytokinetics , Incorporated (NASDAQ:CYTK), a $5.7 billion biopharmaceutical company, has announced the awarding of $100,000 in grants to five patient advocacy organizations ...

Total of $100,000 Awarded to Five Patient Advocacy Organizationsto Support Communications and Community OutreachSOUTH SAN FRANCISCO, Calif., Jan.

Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:CYTK), noting the company’s catalyst rich one to two years.

Cytokinetics, Inc. (CYTK) stock saw a modest uptick, ending the day at $50.75 which represents a slight increase of $2.89 or 6.04% from the prior close of $47.86. The stock opened at $47.75 and ...

Inspire Investing LLC boosted its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 7.8% in the ...

Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Cytokinetics announced that it has begun enrolling patients in its mid-stage study of CK-4021586 (CK-586), a ...

Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Cytokinetics in a ...

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its seventh annual Communications Grant Program ...